To compare the efficacy of once-weekly and once-daily subcutaneous injections of teriparatide (recombinant human parathyroid hormone 1-34) on fracture healing, 50 adult male Sprague-Dawley rats were subjected to a unilateral tibia fracture and received internal fixation with a Kirschner needle. Based on the injection dose and frequency, the rats were randomly divided into five groups (n ¼ 10 each): subcutaneous injections of saline or 10 mg/kg/w, 20 mg/kg/w, 10 mg/kg/d, and 20 mg/kg/d teriparatide. Four weeks later, the rats were euthanatized, and the fractured tibiae were assessed using X-rays, dual-energy X-ray absorptiometry, microcomputed tomography, the three-point bending biomechanics test, and histology. Compared to the saline control group, either daily or weekly subcutaneous injections of teriparatide significantly increased bone mass, improved the bone microarchitecture, and promoted fracture healing (p < 0.05). There were no significant differences in bone mineral density (BMD), bone microstructure or bone strength between the 20 mg/kg/w and 10 mg/kg/d groups (p > 0.05). Teriparatide 20 mg weekly injections promoted bone fracture healing to the same extent as teriparatide 10 mg daily injections, which can dramatically decrease the cumulative dosage of teriparatide injections.
Fractures lead to a serious decline in quality of life and are associated with increased mortality. 1 However, presently, adjuvant treatments to accelerate fracture healing are limited. 1 Thus, the identification of a method to promote fracture healing after osteosynthetic surgery is critical.
Anti-osteoporosis drugs are commonly used to prevent fragility fractures, which is the main purpose of osteoporosis treatment. 2 The majority of antiosteoporosis drugs are antiresorptive agents, such as bisphosphonates, which reduce the capacity of osteoclasts to resorb bone and inhibit osteoblast formation, function, and survival. 3 The other category of antiosteoporosis agents includes anabolic agents, and the most representative medication in this class is parathyroid hormone (PTH). Teriparatide, also known as recombinant human parathyroid hormone (rhPTH ), is the only currently available medicine approved by the US Food and Drug Administration (FDA) as an anabolic therapy for serious osteoporosis. 4 Unlike antiresorptive therapies, intermittent administration of PTH increases bone mass and bone formation and improves bone quality. 4 The treatment of patients with postmenopausal osteoporosis via oncedaily subcutaneous injection of teriparatide reduced the incidence of vertebral fractures by 65% and nonvertebral fractures by 54%. 5 According to some clinical trials, once-weekly administration of teriparatide also reduced the incidence of vertebral fractures. 6 Considering the biological role of these antiosteoporosis drugs in reversing osteoporosis and stimulating bone formation, they may help improve fracture healing. However, when these anti-osteoporosis medications have been used for fracture healing, the effects have been controversial; antiresorptive drugs, such as bisphosphonates and denosumab, could suppress bone resorption activities in an ovariectomized osteoporosis rat model, while they had no significant effect on bone fracture healing. 7, 8 In contrast, preclinical studies using animal fracture models have shown that daily administration of teriparatide improved the morphometric and mechanical properties of calluses at the fracture site and promoted fracture healing. [9] [10] [11] [12] The majority of previous studies used once-daily subcutaneous injections to improve fracture healing or prevent fractures. Some clinical trials used onceweekly injections to treat serious osteoporosis. However, to date, few studies have determined the efficacy of once-weekly subcutaneous teriparatide injections for fracture healing. Since teriparatide can augment bone mass, increase bone formation and improve bone quality by stimulating osteoblast activities and increasing the bone-remodeling rate, onceweekly injections may produce these effects to promote fracture healing. Considering that teriparatide is an expensive biological agent, daily subcutaneous teriparatide injections require a large and costly dose, and patient compliance is difficult to maintain, which may have an impact on the treatment effect. 13 Therefore, in our current study, we compared the efficacy of once-weekly and once-daily subcutaneous teriparatide injections for fracture healing to reduce the cost of the treatment.
MATERIALS AND METHODS

Animals and Experimental Design
Fifty 12-week-old male Sprague-Dawley rats weighing approximately 300 g each were used in this experiment. The rats were housed under specific-pathogen-free conditions with a 12-h light-dark cycle and were provided free access to standard laboratory feed and clean water. All experimental procedures and protocols were approved by the Peking University Third Hospital Committee on Ethics for the Care and Use of Laboratory Animals.
After 1-week acclimation, all animals were randomly allocated to five groups (n ¼ 10 for each group). The four treatment groups received subcutaneous injections of teriparatide (S20110021, Lilly, Fegersheim, France), whereas the control group received an equal volume of 0.9% saline. Based on the teriparatide injection dose (10 or 20 mg/kg) and frequency (once daily or once weekly), the four treatment groups were specifically referred to as the 10 mg/kg/d, 20 mg/kg/d, 10 mg/kg/w, and 20 mg/kg/w groups. The injections were initiated on the second day after the experimental fracture, the body weights were measured weekly, and doses were adjusted accordingly. After 1 month, the rats were euthanized with excessive anesthesia, and tibiae were excised and wrapped in gauze soaked in isotonic saline and frozen at À80˚C for subsequent experiments. Six tibiae randomly selected from each group were used for micro-CT, dual-energy X-ray absorptiometry (DXA) and biomechanical tests, and the other four tibiae from each group were used for histology.
Rat Tibia Fracture Model
All rats underwent surgery to produce mid-diaphyseal fractures of the left tibiae using a previously reported method. 14, 15 The animals were anesthetized with an intraperitoneal injection of 10% chloral hydrate (3.3 ml/kg). A 1-cm incision was made anterior to the upper end of the right tibia through the skin and the subcutaneous tissues, and the tibia plateau was exposed under sterile conditions. A saw blade (BS1232, Starrett, Athol, MA) was used to create a mid-diaphyseal fracture of the proximal tibia, the bone was continuously irrigated with cool saline solution, and the surrounding soft tissue was protected against damage. Then, intramedullary fixation was performed with a Kirschner wire (w 1 mm), and the muscles and the skin were sutured using 4/0 silk. After the operation, the 50 rats were randomly divided into control, 10 mg/kg/d, 20 mg/kg/d, 10 mg/kg/w, and 20 mg/kg/w groups.. The activities and movements of the rats were not restricted after they regained consciousness.
The animal fracture model was successfully established, and the postoperative recovery was good. There were no obvious signs of infection or significant adverse reactions.
Radiography
Lateral radiographs of the fractured tibiae were captured with a high-frequency portable X-ray machine (60 kVp, 5 mA, LX-24HA, Longsafe Imaging, Co., Ltd., Beijing, China) immediately after the operation and 1, 2, 3, and 4 w after the operation to assess the fracture alignment and fixation. The Lane and Sandhu system was used to evaluate the fracture healing at different time points. 16 The Lane and Sandhu system is scored from 0 to 12 points, with scores summed from three dimensions: Bone formation at the fracture gap, the presence of the fracture line and evidence of remodeling. Each dimension is scored as 0, 2, or 4 points.
Micro-Computed Tomography (Micro-CT)
To evaluate fracture healing and callus formation, the tibiae were scanned by micro-CT using an Inveon MM system (Siemens, Erlangen, Germany) at an effective pixel size of 8.82 mm, current of 500 mA, voltage of 80 kV, and exposure time of 1,500 ms in each of the 360 rotational steps. 17 We counted 150 axial slices distal and proximal to the fracture line, approximately 2.65 mm, as the first region of interest (ROI), 18 and the following parameters were calculated using multimodal 3D visualization software (Inveon Research Workplace, Siemens, Erlangen, Germany): total callus volume (TV callus ), mineralized callus volume (BV callus ), and ratio of the mineralized tissue within the total callus volume (BV callus /TV callus ).
According to the guidelines set by the American Society for Bone and Mineral Research, 19 we selected the second ROI in the trabecular region (150 axial slices, approximately 1.3 mm distal to the proximal epiphyseal plate), and the bone volume/total volume (BV/TV), trabecular thickness (Tb.Th), trabecular number (Tb.N) and trabecular separation (Tb.Sp) were calculated using multimodal 3D visualization software (Inveon Research Workplace, Siemens, Germany). 17 The threshold value (1,000-2,500 HU) was adjusted as appropriate for the mineralized bone phase.
Bone Mineral Density (BMD)
The Kirschner wire of the six randomly selected tibiae from each group was carefully removed to ensure that the callus of the tibiae was not damaged. Then, the BMD of these tibiae was measured by DXA with a small-animal high-resolution collimator (Discovery TM , Hologic, Inc., Boston, MA). The ROI was established at the midpoint of the tibia as a 0.8 Â 1-cm 2 rectangular area, with the transverse fracture site located at the center of the area. One technician blinded to the experimental design analyzed the DXA data.
Biomechanics
Immediately after measuring the BMD, a three-point bending test was performed on the fracture site of these tibiae using a mechanical testing system (Landmark, MTS, Inc., Eden Prairie, MN) to determine the mechanical properties. 20 During the process, the tibiae were continuously moistened with an isotonic saline solution. The two condyles of each tibia were placed in the free notches of an aluminum alloy base. A preload of 1 N was used to fix the tibia on the device, and a bending force was applied at a speed of 2 mm/min for the test. The strength of the tibia was determined as the maximal force that caused complete failure of the tibia.
17,21
Histology
The remaining four tibiae from each group were fixed with 10% neutral buffered formalin, dehydrated in an increasing gradient of alcohol solutions, and embedded in methylmethacrylate resin. Undecalcified sections were cut and ground at a 30-mm thickness parallel to the long axis of the tibia (EXAKT Cutting & Grinding System, Norderstedt, Germany). Then, the undecalcified sections were stained with Goldner's trichrome and observed with a stereomicroscope (SMZ745T, Nikon, Tokyo, Japan). Mature trabecular bone and osteoid were stained green and red, respectively. 
Statistics
All data are presented as the means AE standard deviation (SD) after statistical analysis with SPSS 18.0 (Chicago, IL). A two-way analysis of variance (ANOVA) with interaction analysis was used to analyze the effects of dose and frequency and their interaction on the results. A simpleeffect analysis was used if there was an interaction between dose and frequency. Based on the simple-effect analysis results, four groups (combinations of two doses and two frequencies) were compared with a one-way ANOVA, and the significance of the post hoc analysis for each two groups was adjusted with Fisher's least significant difference (LSD) method. A p-value of <0.05 was considered statistically significant.
RESULTS
Radiography X-rays performed at different time points after the operation showed that the subcutaneous injection of teriparatide significantly promoted fracture healing. The fracture lines were almost invisible in the rats in the teriparatide-treated groups, whereas the fracture lines were still visible in the control group 4 weeks after the fracture (Fig. 1) . Even more interestingly, the fractures healed more rapidly in the 20 mg/kg/w teriparatide-treated group than that in the 10 mg/kg/w and control groups. However, significant differences in fracture healing were not observed between the 20 mg/kg/w and 10 mg/kg/d groups. The fracture healing scores in each group, according to the LaneSandhu radiographic system, are shown in Table 1 .
BMD
The results of BMD showed that the subcutaneous teriparatide injections significantly increased the BMD in the tibiae of the teriparatide-treated rats compared to the control group (p < 0.05). Regarding the teriparatide-treated groups, the BMD in the 20 mg/kg/w group was significantly higher than that in the 10 mg/kg/w group (p < 0.05), but there was no significant difference between the 20 mg/kg/w and 10 mg/kg/d groups (p > 0.05) (Fig. 2) .
The results of a two-way ANOVA and the interaction analysis showed that there was an interaction between the dose and frequency of teriparatide according to the BMD values (Table 2) , which means that increasing the frequency at low doses can yield great benefits, while increasing the frequency at high doses may not be as obviously beneficial as that at low doses. Similarly, increasing the dose at a low frequency can yield much greater benefits than increasing the dose at a high frequency.
Micro-CT
Micro-CT images showed that the subcutaneous teriparatide injections promoted callus formation at the fracture site and improved the microstructure of the Figure 1 . Representative radiographs of the control and treated groups immediately after surgery and from the 1st, 2nd, 3rd, and 4th week after surgery. The callus gradually increased, and the fracture lines gradually blurred and were almost invisible in the treated groups at the 4th week after surgery. rhPTH (1-34) PROMOTES FRACTURE HEALING tibia compared to the tibiae of the control group (Fig. 3) .
According to the quantitative analysis of the micro-CT images of the fracture site, the TV callus , BV callus , and BV callus /TV callus values in the 20 mg/kg/w group were significantly higher than the values in the control and 10 mg/kg/w groups (p < 0.05), but no significant differences were observed between the 20 mg/kg/w and 10 mg/kg/d groups (p > 0.05) (Fig. 4) .
A quantitative analysis of the micro-CT results in the proximal tibia revealed that the subcutaneous teriparatide injections also significantly increased the BV/TV, Tb.Th, and Tb.N and decreased the Tb.Sp in the 20 mg/kg/w group compared to the control and 10 mg/kg/w groups (p < 0.05). There was no significant difference between the 20 mg/kg/w and 10 mg/kg/d groups (p > 0.05) (Fig. 5) .
Biomechanics
Subcutaneous teriparatide injections significantly increased the maximum load force of the tibiae from the treated groups compared to the tibiae from the control group (p < 0.01). Regarding the teriparatide-treated groups, the maximum load force of the tibiae in the 20 mg/kg/w group was significantly higher than that in the 10 mg/kg/w group (p < 0.05). No significant difference was observed between the 20 mg/kg/w and 10 mg/kg/d groups (p > 0.05) (Fig. 6 ).
Histology
The results of Goldner's trichrome staining showed that the mature trabecular bone was stained green, while the osteoid was stained red. 17, 22 According to the qualitative assessment of the histological sections, the subcutaneous teriparatide injections increased the formation of mature trabecular bone compared to the control group (Fig. 7) .
DISCUSSION
PTH (1-34) (teriparatide), which is the N-terminal peptide of the parent hormone PTH and is responsible for serum calcium homeostasis, was initially approved for the treatment of osteoporosis in women and the prevention of bone loss in men. 23 Although the process of fracture healing is very complicated and involves remodeling processes, osteoporosis and bone fractures share some features, such as the stimulation of bone modeling. 24 Intermittent teriparatide administration has a potent stimulatory effect on bone modeling, as reflected by the increased cancellous and cortical bone mass, improved bone microarchitecture, and reduced risk of vertebral fractures in osteoporotic patients. 24 Intermittent administration of teriparatide dramatically increases not only bone formation but also bone resorption. However, because the balance favors bone formation, the bone mass increases in bone formation. 13, 25 Antiresorptive drugs, such as bisphosphonates, can prevent further bone loss by inhibiting bone resorption. 26 These findings led to the hypothesis that the combination of anabolic PTH (1-34) and bisphosphonates may simultaneously inhibit excessive bone resorption and stimulate new bone formation. 20 However, the results of many studies have shown that the effects of PTH (1-34) can be attenuated by bisphosphonates since combination therapy is probably better than alendronate alone, while parathyroid hormone alone is better than combination therapy. The most plausible explanation is that bisphosphonates inhibit overall bone turnover, which impairs the anabolic activity of PTH (1-34) . The available data indicate that PTH (1-34) acts mainly on mature osteoblasts to enhance their function, their lifespan, or both, and it may also enhance the differentiation of cells in the osteoblastic lineage. 29, 30 Thus, if bone turnover is inhibited by bisphosphonates, bone formation is reduced, and parathyroid hormone may be less effective since fewer of its osteoblast targets are available.
The molecular mechanisms of the pro-differentiating effects of intermittent PTH administration involve its upregulation of the osteoblast-specific transcription factor runt-related transcription factor 2, alkaline phosphatase and type I procollagen in cultured bone marrow or calvaria cells, which requires BMP and Wnt signaling and involves the stimulation of Smad1/ 5/8 activity and b-catenin-mediated transcription. 31, 32 Previous studies have indicated that PTH could dramatically upregulate the mRNA expression of osteoprotegerin on day 7 post-fracture and the mRNA expression of bone matrix proteins (type I collagen, osteonectin, and osteocalcin) and alkaline phosphatase after day 7 post-fracture. 33 Based on the effects of teriparatide on increasing the BMD and improving bone microarchitecture in osteoporosis patients, furthermore, the anabolic response of intermittent rhPTH (1-34) administration was more robust at sites of injury versus non-wounded bone. 34 We speculated that teriparatide could also promote bone fracture healing.
As shown in some clinical studies, a daily 20 mg or weekly 56.5 mg teriparatide subcutaneous injections significantly reduced the risks of vertebral and non-vertebral fractures. [35] [36] [37] [38] [39] [40] [41] Moreover, once-weekly teriparatide subcutaneous injections increased bone mass, bone microstructure and mechanical properties in ovariectomized osteoporotic monkeys. 42 According to some case reports, weekly teriparatide subcutaneous injections were useful for the treatment of fracture or delayed union. [43] [44] [45] These preclinical studies of the effects of teriparatide or PTH (1-34) on promoting fracture healing in animal fracture models used daily injections, [46] [47] [48] twice-weekly injections, 49 thrice-weekly injections, 11 or once-weekly injections with relatively high doses. 12, 50 The common characteristic of these preclinical studies is that they lack a direct comparison of the effects of teriparatide or rhPTH (1-34) on fracture healing between different injection methods, that is, once-weekly and daily administration, the results of which may be partially affected by sample collection conditions or individual differences between animals.
In this study, compared to the saline control group, teriparatide treatment indeed increased the cortical and cancellous bone mass, improved the bone microarchitecture at the fracture site, and promoted fracture healing in both the daily injection group and the weekly injection group. Further analysis of the teriparatide-treated group did not reveal significant differences in the radiographic, BMD, bone microstructure, or bone strength parameters between the 20 mg/ kg/w and 10 mg/kg/d groups, suggesting that weekly teriparatide injections promoted bone fracture healing to the same extent as the daily injections under the same conditions. The results of a two-way ANOVA of BMD showed that increasing the frequency at low doses can yield great benefits, while increasing the frequency at high doses may not be as obviously beneficial as that at low doses. These findings imply that once-weekly injections of a higher dose of teriparatide might be feasible for treating osteoporosis or promoting bone fracture healing, but the optimal dose should be further explored in future research.
Moreover, a single subcutaneously injection of teriparatide has been reported to increase the levels of serum bone formation markers, such as procollagen type I N-terminal propeptide and osteocalcin, by approximately 10% and last over 14 days. However, bone resorption markers, such as cross-linked N-telopeptide of type I collagen and cross-linked C-telopeptide of type I collagen, decreased 10-12% and lasted over 14 days. 13 These findings might imply that weekly or even biweekly subcutaneous injections of teriparatide might be effective for bone formation.
Although daily subcutaneous injections of teriparatide showed many clinical benefits, including reduced risk of fracture and improved patient quality of life as well as good effects on promoting bone fracture healing in preclinical studies, the daily self-administration regimen is burdensome, particularly for elderly patients. Furthermore, teriparatide is a biological agent that may cause many side effects, and its high cost may represent a substantial economic burden for patients. These findings provide substantial evidence of the effect of weekly subcutaneous teriparatide injection on promoting bone fracture healing. Based on our current experimental results, weekly teriparatide injections dramatically decrease the dosage and may improve patient adherence and maintenance to the therapy, which will greatly reduce the treatment cost and compensate for its shortcomings.
The limitations of our present study are that we chose only two doses (10 and 20 mg/kg) and did not determine the optimal dosage for weekly injection to achieve the same or better effects on promoting fracture healing as 20 mg/kg daily injections. We neither explored the cellular mechanisms responsible for the results of weekly therapy nor examined the differences between once-daily and once-weekly teriparatide injections in terms of factors such as stem cell recruitment and differentiation or the effects of weekly treatment on gene expression, which will be examined in future studies.
In conclusion, the treatment of rat tibia fractures with weekly rhPTH (1-34) injections could promote bone fracture healing, which could decrease the cumulative dosage of rhPTH injections.
AUTHORS' CONTRIBUTIONS
Designed the research studies: WZ and CLS. Conducted the experiments: WZ, CL, TM, and BH. Acquired the data: WZ, HW, JXZ, and YSX. Analyzed the data: WZ, GHD, HW, NL, and CLS. Provided reagents: WZ, JXZ, and YSX. Wrote the manuscript: WZ and CLS. All the authors have read and approved the final submitted manuscript.
